April 27th 2023

Published in iScience: A new optimized SARS-CoV-2 phenotypic screening platform

Published in iScience: A new  optimized SARS-CoV-2 phenotypic screening platform

The CARE partner Goethe University Frankfurt Institute of Medical Virology, published a paper reporting on a novel phenotypic screening platform for the identification of drug candidates with activity against SARS-CoV-2 and other coronaviruses. This successful proof of concept was based on the determination of caspase 3/7 activity using the one-step Caspase-Glo 3/7 Assay System as readout. This platform uses the Caco-2-F03 cell line which demonstrated susceptibility to a broad range of SARS-CoV-2 without being affected by phospholipidosis, a known cause of false-positive hits, and is also considered suitable for neutralisation assays and phenotypic resistance testing.

To learn more, click here: Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform